(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 September 2013 (26.09.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/141730 A1

(51) International Patent Classification:
*A61K 35/76* (2006.01) *A61K 38/18* (2006.01)
*A61P 31/04* (2006.01)

(21) International Application Number:
PCT/PT2013/000016

(22) International Filing Date:
19 March 2013 (19.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/612,531 19 March 2012 (19.03.2012) US

(71) Applicants: **TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A.** [PT/PT]; Rua Tierno Galvan, Torre 3, 12 Piso, P-1099-036 Lisboa (PT). **TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA** [PT/PT]; Avenida Professor Egas Moniz, Edificio Egas Moniz, piso 2, sala A8, P-1649-028 Lisboa (PT).

(72) Inventors: **ALVES MENDES, João Duarte**; Rua José de Oliveira Raposo nº3 R/C esq., P-2770-093 Paço de Arcos (PT). **RODRIGUES LEANDRO, Clara Isabel**; Praceta Eugénio Salvador, Lt-10, R/c-C, P-2775-089 Parede (PT). **VOLKER CÔRTE-REAL, Sofia**; Rua dos Bombeiros Vol. do Dafundo nº 2 2ºJ, P-1495-714 Cruz Quebrada (PT).

(74) Agent: **VIEIRA PEREIRA FERREIRA, Maria Silvina**; Clarke, Modet & Co., Rua Castilho, 50-9º, P-1269-163 Lisboa (PT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/141730 A1

(54) **Title**: COMPOSITIONS COMPRISING COCKTAILS OF ANTIBACTERIAL PHAGES AND USES THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

(57) **Abstract**: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular diabetic foot infections. More specifically, the present invention is directed to novel cocktails of bacteriophage strains F44/10, Fl 25/10, F770/05, F510/08, Fl 245/05, and/or variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including cutaneous ulcers associated with diabetic foot infections, caused by, e.g., Staphylococcus aureus, Pseudomonas aeruginosa, and/or Acinetobacter baumannii. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics, growth factors, or other standard, as well as non-standard, therapies for diabetic foot infections.